156 related articles for article (PubMed ID: 24450915)
1. An outbreak of exposure to a novel synthetic cannabinoid.
Monte AA; Bronstein AC; Cao DJ; Heard KJ; Hoppe JA; Hoyte CO; Iwanicki JL; Lavonas EJ
N Engl J Med; 2014 Jan; 370(4):389-90. PubMed ID: 24450915
[No Abstract] [Full Text] [Related]
2. Case Series of Synthetic Cannabinoid Intoxication from One Toxicology Center.
Katz KD; Leonetti AL; Bailey BC; Surmaitis RM; Eustice ER; Kacinko S; Wheatley SM
West J Emerg Med; 2016 May; 17(3):290-4. PubMed ID: 27330661
[TBL] [Abstract][Full Text] [Related]
3. A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA.
Schwartz MD; Trecki J; Edison LA; Steck AR; Arnold JK; Gerona RR
J Emerg Med; 2015 May; 48(5):573-80. PubMed ID: 25726258
[TBL] [Abstract][Full Text] [Related]
4. Occupational transdermal poisoning with synthetic cannabinoid cumyl-PINACA.
Dobaja M; Grenc D; Kozelj G; Brvar M
Clin Toxicol (Phila); 2017 Mar; 55(3):193-195. PubMed ID: 28084855
[TBL] [Abstract][Full Text] [Related]
5. Coma, Seizures, Atrioventricular Block, and Hypoglycemia in an ADB-FUBINACA Body-Packer.
Nacca N; Schult R; Loflin R; Weltler A; Gorodetsky R; Kacinko S; Moran J; Krotulski A; Wiegand T
J Emerg Med; 2018 Dec; 55(6):788-791. PubMed ID: 30297193
[TBL] [Abstract][Full Text] [Related]
6. Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA.
Shanks KG; Clark W; Behonick G
J Anal Toxicol; 2016 Apr; 40(3):236-9. PubMed ID: 26755539
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Synthetic Cannabinoid Deaths in State of Florida Prisoners.
Hvozdovich JA; Chronister CW; Logan BK; Goldberger BA
J Anal Toxicol; 2020 Apr; 44(3):298-300. PubMed ID: 31776572
[TBL] [Abstract][Full Text] [Related]
8. Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.
Sznitman SR; Pinsky-Talbi L; Salameh M; Moed T; Bentur Y
Int J Drug Policy; 2020 Mar; 77():102711. PubMed ID: 32126489
[TBL] [Abstract][Full Text] [Related]
9. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.
Hermanns-Clausen M; Müller D; Kithinji J; Angerer V; Franz F; Eyer F; Neurath H; Liebetrau G; Auwärter V
Clin Toxicol (Phila); 2018 Jun; 56(6):404-411. PubMed ID: 29072524
[TBL] [Abstract][Full Text] [Related]
10. Notes from the field: severe illness associated with reported use of synthetic marijuana - Colorado, August-September 2013.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2013 Dec; 62(49):1016-7. PubMed ID: 24336136
[TBL] [Abstract][Full Text] [Related]
11. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA.
Tyndall JA; Gerona R; De Portu G; Trecki J; Elie MC; Lucas J; Slish J; Rand K; Bazydlo L; Holder M; Ryan MF; Myers P; Iovine N; Plourde M; Weeks E; Hanley JR; Endres G; St Germaine D; Dobrowolski PJ; Schwartz M
Clin Toxicol (Phila); 2015; 53(10):950-6. PubMed ID: 26555732
[TBL] [Abstract][Full Text] [Related]
12. Synthetic cannabinoid poisoning: A growing health concern.
Phillips J; Lim F; Hsu R
Nursing; 2016 Nov; 46(11):34-41. PubMed ID: 27673323
[No Abstract] [Full Text] [Related]
13. Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption.
Kovács K; Kereszty É; Berkecz R; Tiszlavicz L; Sija É; Körmöczi T; Jenei N; Révész-Schmehl H; Institóris L
J Forensic Leg Med; 2019 Jul; 65():92-100. PubMed ID: 31128567
[TBL] [Abstract][Full Text] [Related]
14. Notes from the Field: Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol - Utah, 2017-2018.
Horth RZ; Crouch B; Horowitz BZ; Prebish A; Slawson M; McNair J; Elsholz C; Gilley S; Robertson J; Risk I; Hill M; Fletcher L; Hou W; Peterson D; Adams K; Vitek D; Nakashima A; Dunn A
MMWR Morb Mortal Wkly Rep; 2018 May; 67(20):587-588. PubMed ID: 29795081
[No Abstract] [Full Text] [Related]
15. Synthetic legal intoxicating drugs: the emerging 'incense' and 'bath salt' phenomenon.
Jerry J; Collins G; Streem D
Cleve Clin J Med; 2012 Apr; 79(4):258-64. PubMed ID: 22473725
[TBL] [Abstract][Full Text] [Related]
16. Synthetic cannabinoid use in New Zealand: a recent rebound.
Schep LJ; Slaughter RJ; Temple WA; Lambie BS; Gee P; Watts M; Gresham C
N Z Med J; 2012 Oct; 125(1364):114-6. PubMed ID: 23242407
[No Abstract] [Full Text] [Related]
17. Synthetic Cannabinoid-Related Illnesses and Deaths.
Trecki J; Gerona RR; Schwartz MD
N Engl J Med; 2015 Jul; 373(2):103-7. PubMed ID: 26154784
[No Abstract] [Full Text] [Related]
18. Clinical Pharmacists: Essential During a Poison Outbreak.
Routsolias JC; Gimbar RP; Zell-Kanter M
J Med Toxicol; 2020 Oct; 16(4):356-357. PubMed ID: 32638283
[No Abstract] [Full Text] [Related]
19. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
[TBL] [Abstract][Full Text] [Related]
20. An outbreak of synthetic cannabinoid exposures reported to a regional poison center: "K2" identified as 5F-ADB.
Arens AM; Olives TD; Simpson NS; Laes JR; Anderson DL; Bangh SA; Lee SC; Martin S; Banister SD; Gerona RR; Cole JB
Clin Toxicol (Phila); 2019 Jan; 57(1):69-71. PubMed ID: 30430881
[No Abstract] [Full Text] [Related]
[Next] [New Search]
